MTOR and neoplasm: In addition, reverse-phase protein assay (18) data from 7,663 TCGA patient samples from 31 tumor types demonstrated that p-4EBP1 and mTOR activity, but not p-S6K activity, was associated with poor prognosis (Supplemental Figure 1, C–E), indicating the importance of 4EBP1 dysregulation in tumor progression (19, 20).